Trials / Completed
CompletedNCT04695405
Pharmacogenetics Associated With IV Ketamine
Genetic Markers Associated With Response to Intravenous Ketamine
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 85 (actual)
- Sponsor
- Brain and Cognition Discovery Foundation · Academic / Other
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
The Canadian Rapid Treatment Center of Excellence (CRTCE) is a healthcare facility principally focused on providing best practices of intravenous ketamine treatment to adult patients suffering from treatment resistant depression. Patients who have received IV ketamine at the clinic are eligible to participate in this study where genetic biomarkers are correlated with response to IV ketamine.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| GENETIC | Saliva Genetic Samples | Patients will provide two saliva swabs containing genetic materials. |
Timeline
- Start date
- 2021-01-21
- Primary completion
- 2021-07-02
- Completion
- 2021-07-02
- First posted
- 2021-01-05
- Last updated
- 2021-08-18
Locations
1 site across 1 country: Canada
Source: ClinicalTrials.gov record NCT04695405. Inclusion in this directory is not an endorsement.